Cumberland pharmaceuticals announces breakthrough results from the phase 2 fight dmd trial in duchenne muscular dystrophy heart disease

Nashville, tenn. , feb. 4, 2025 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its phase 2 fight dmd trial.
CPIX Ratings Summary
CPIX Quant Ranking